Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
To evaluate the efficacy and safety of routine P-CAB use in patients with coronary artery disease who underwent PCI and maintain DAPT, as compared to guideline-directed proton pump inhibitor (PPI) usage.
Study Type
OBSERVATIONAL
Enrollment
100,000
This group received P-CAB with DAPT after PCI.
This group received PPI or not with DAPT after PCI according to GI bleeding risk.
Samsung Medical Center
Seoul, South Korea
RECRUITINGMajor GI bleeding
Major GI bleeding requiring transfusion
Time frame: at 1 year
Clinically relevant GI bleeding
Clinically relevant GI bleeding
Time frame: At 1 year
Major adverse cardiac event
A composite of cardiovascular death, myocardial infarction, and repeat revascularization
Time frame: At 1 year
Cardiovascular death
Cardiovascular death
Time frame: At 1 year
Myocardial infarction
Myocardial infarction
Time frame: At 1 year
Repeat revascularization
Repeat revascularization
Time frame: At 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.